Suresh Alaparthy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow et al. · New England Journal of Medicine · 2012 · 8K citations · Full text

Life Sciences, Immunology, Oncology +17

An immune-active tumor microenvironment favors clinical response to ipilimumab

Rui‐Ru Ji, Scott D. Chasalow, Lisu Wang et al. · Cancer Immunology Immunotherapy · 2011 · 777 citations · Full text

Medicine, Immunology, Oncology +10

Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.

Naiyer A. Rizvi, Laura Q.M. Chow, Hossein Borghaei et al. · Journal of Clinical Oncology · 2014 · 119 citations

Medicine, Oncology, Pharmacology +12

First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.

Scott Gettinger, Frances A. Shepherd, Scott Antonia et al. · Journal of Clinical Oncology · 2014 · 103 citations

Medicine, Oncology, Pharmacology +17

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

Vafa Shahabi, Gena S. Whitney, Omid Hamid et al. · Cancer Immunology Immunotherapy · 2012 · 84 citations · Full text

Medicine, Genetics, Oncology +14